# US 2026/0098096 A1 · Anti-ccr8 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098096 A1
- Document ID: US20260098096A1
- Status: Published application
- Kind: A1
- Application number: 19/113,897
- Filed: 2023-09-21
- Published: 2026-04-09
- Earliest claimed: 2022-09-21
- Assignees: Monash University
- Applicants: Monash University
- Inventors: Remy Michel ROBERT
- Web page: https://patentgrep.com/patent/US20260098096A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to antigen binding proteins and related fragments thereof for binding to CCR8, to production of said antigen binding proteins and fragments and to use of said antigen binding proteins and fragments for detection and therapy of various conditions.

## Claims

### Claim 1

An antigen binding protein that binds to or specifically binds to the extracellular loop 2 of CCR8.

### Claim 2 (depends on 1)

The antigen binding protein of claim 1, wherein the antigen binding protein binds to residues 172 to 202 of CCR8, preferably residues 172 to 190 of CCR8, wherein the amino acid sequence of CCR8 is as set forth in SEQ ID NO: 55.

### Claim 3 (depends on 1, 2)

The antigen binding protein of claim 1 or 2, wherein the antigen binding protein binds to residues 176 to 179 of CCR8, wherein the amino acid sequence of CCR8 is as set forth in SEQ ID NO: 55.

### Claim 4 (depends on 1, 2, 3)

The antigen binding protein of any one of claims 1 to 3, wherein the antigen binding protein does not block binding of CCR8 to CCL1.

### Claim 5

An antigen binding protein comprising a CDRH1, a CDRH2 and/or a CDRH3 of an antibody having a variable heavy chain as defined in SEQ ID NO: 1 and a CDRL1, a CDRL2 and/or a CDRL3 of an antibody having a variable light chain as defined in SEQ ID NO: 2.

### Claim 6

An antigen binding protein that binds to or specifically binds to CCR8 and wherein the antigen binding protein competitively inhibits the binding of an antibody comprising: a VH comprising a sequence as set forth in SEQ ID NO: 1 and a VL comprising a sequence as set forth in SEQ ID NO: 2; or a VH comprising a sequence as set forth in SEQ ID NO: 83 and a VL comprising a sequence as set forth in SEQ ID NO: 84.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The antigen binding protein of any one of claims 1 to 6, wherein the antigen binding protein comprises an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CCR8, wherein the antigen binding domain comprises at least one of:
(i) a VH comprising a complementarity determining region (CDR) 1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 5, a CDR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99% identical to a sequence set in SEQ ID NO: 6, and a CDR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99% identical to a sequence set forth in SEQ ID NO: 7;
(ii) a VH comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 1 or 83;
(iii) a VL comprising a CDR1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 8, a CDR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 9, and a CDR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 10;
(iv) a VL comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 2 or 84;
(v) a VH comprising a CDR1 comprising a sequence set forth in SEQ ID NO: 5, a CDR2 comprising a sequence set forth between in SEQ ID NO: 6, and a CDR3 comprising a sequence set forth in SEQ ID NO: 7;
(vi) a VH comprising a sequence set forth in SEQ ID NO: 1 or 83;
(vii) a VL comprising a CDR1 comprising a sequence set SEQ ID NO: 8, a CDR2 comprising a sequence set forth in SEQ ID NO: 9 and a CDR3 comprising a sequence set forth in SEQ ID NO: 10;
(viii) a VL comprising a sequence set forth in SEQ ID NO: 2 or 84;
(ix) a VH comprising a CDR1 comprising a sequence set forth in SEQ ID NO: 5, a CDR2 comprising a sequence set forth between in SEQ ID NO: 6 and a CDR3 comprising a sequence set forth in SEQ ID NO: 7; and a VL comprising a CDR1 comprising a sequence set SEQ ID NO: 8, a CDR2 comprising a sequence set forth in SEQ ID NO: 9 and a CDR3 comprising a sequence set forth in SEQ ID NO: 10;
(x) a VH comprising a sequence set forth in SEQ ID NO: 1 and a VL comprising a sequence set forth in SEQ ID NO: 2,
(xi) a VH comprising a sequence set forth in SEQ ID NO: 83 and a VL comprising a sequence set forth in SEQ ID NO: 84.

### Claim 8 (depends on 7)

The antigen binding domain of claim 7, further comprising at least one of:
(i) a VH comprising a framework region (FR) 1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 11, a FR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set in SEQ ID NO: 12, a FR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 13, and a FR4 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 14;
(ii) a VL comprising a FR1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 15, a FR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 16, a FR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 17, and a FR4 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 18;
(iii) a VH comprising a FR1 comprising a sequence set forth in SEQ ID NO: 11, a FR2 comprising a sequence set forth between in SEQ ID NO: 12, a FR3 comprising a sequence set forth in SEQ ID NO: 13, and a FR4 comprising a sequence set forth in SEQ ID NO: 14;
(iv) a VL comprising a FR1 comprising a sequence set forth in SEQ ID NO: 15, a FR2 comprising a sequence set forth between in SEQ ID NO: 16, a FR3 comprising a sequence set forth in SEQ ID NO: 17, and a FR4 comprising a sequence set forth in SEQ ID NO: 18; or
(v) a VH comprising a FR1 comprising a sequence set forth in SEQ ID NO: 11, a FR2 comprising a sequence set forth between in SEQ ID NO: 12, a FR3 comprising a sequence set forth in SEQ ID NO: 13, and a FR4 comprising a sequence set forth in SEQ ID NO: 14; and a VL comprising a FR1 comprising a sequence set forth in SEQ ID NO: 15, a FR2 comprising a sequence set forth between in SEQ ID NO: 16, a FR3 comprising a sequence set forth in SEQ ID NO: 17, and a FR4 comprising a sequence set forth in SEQ ID NO: 18.

### Claim 9 (depends on 7)

The antigen binding domain of claim 7, further comprising at least one of:
(i) a VH comprising a framework region (FR) 1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 60, a FR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set in SEQ ID NO: 61, a FR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 62, and a FR4 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 63;
(ii) a VL comprising a FR1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 64, a FR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 65, a FR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 66, and a FR4 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 67;
(iii) a VH comprising a FR1 comprising a sequence set forth in SEQ ID NO: 60, a FR2 comprising a sequence set forth between in SEQ ID NO: 61, a FR3 comprising a sequence set forth in SEQ ID NO: 62, and a FR4 comprising a sequence set forth in SEQ ID NO: 63;
(iv) a VL comprising a FR1 comprising a sequence set forth in SEQ ID NO: 64, a FR2 comprising a sequence set forth between in SEQ ID NO: 65, a FR3 comprising a sequence set forth in SEQ ID NO: 66, and a FR4 comprising a sequence set forth in SEQ ID NO: 67; or
(v) a VH comprising a FR1 comprising a sequence set forth in SEQ ID NO: 60, a FR2 comprising a sequence set forth between in SEQ ID NO: 61, a FR3 comprising a sequence set forth in SEQ ID NO: 62, and a FR4 comprising a sequence set forth in SEQ ID NO: 63; and a VL comprising a FR1 comprising a sequence set forth in SEQ ID NO: 64, a FR2 comprising a sequence set forth between in SEQ ID NO: 65, a FR3 comprising a sequence set forth in SEQ ID NO: 66, and a FR4 comprising a sequence set forth in SEQ ID NO: 67.

### Claim 10 (depends on 5, 6)

The antigen binding protein of claim 5 or 6, wherein the antigen binding protein comprises an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CCR8, wherein the antigen binding domain comprises at least one of:
(i) a VH comprising a complementarity determining region (CDR) 1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 19, a CDR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99% identical to a sequence set in SEQ ID NO: 20, and a CDR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 99% identical to a sequence set forth in SEQ ID NO: 21;
(ii) a VH comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 1 or 83;
(iii) a VL comprising a CDR1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 22, a CDR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 23, and a CDR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 10;
(iv) a VL comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 2 or 84;
(v) a VH comprising a CDR1 comprising a sequence set forth in SEQ ID NO: 19, a CDR2 comprising a sequence set forth between in SEQ ID NO: 20, and a CDR3 comprising a sequence set forth in SEQ ID NO: 21;
(vi) a VH comprising a sequence set forth in SEQ ID NO: 1 or 83;
(vii) a VL comprising a CDR1 comprising a sequence set SEQ ID NO: 22, a CDR2 comprising a sequence set forth in SEQ ID NO: 23 and a CDR3 comprising a sequence set forth in SEQ ID NO: 10;
(viii) a VL comprising a sequence set forth in SEQ ID NO: 2 or 84;
(ix) a VH comprising a CDR1 comprising a sequence set forth in SEQ ID NO: 19, a CDR2 comprising a sequence set forth between in SEQ ID NO: 20 and a CDR3 comprising a sequence set forth in SEQ ID NO: 21; and a VL comprising a CDR1 comprising a sequence set SEQ ID NO: 22, a CDR2 comprising a sequence set forth in SEQ ID NO: 23 and a CDR3 comprising a sequence set forth in SEQ ID NO: 10;
(x) a VH comprising a sequence set forth in SEQ ID NO: 1 and a VL comprising a sequence set forth in SEQ ID NO: 2; or
(xi) a VH comprising a sequence set forth in SEQ ID NO: 83 and a VL comprising a sequence set forth in SEQ ID NO: 84.

### Claim 11 (depends on 10)

The antigen binding domain of claim 10, further comprising at least one of:
(i) a VH comprising a framework region (FR) 1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 24, a FR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set in SEQ ID NO: 25, a FR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 26, and a FR4 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 14;
(ii) a VL comprising a FR1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 27, a FR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 28, a FR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 29, and a FR4 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 18;
(iii) a VH comprising a FR1 comprising a sequence set forth in SEQ ID NO: 24, a FR2 comprising a sequence set forth between in SEQ ID NO: 25, a FR3 comprising a sequence set forth in SEQ ID NO: 26, and a FR4 comprising a sequence set forth in SEQ ID NO: 14;
(iv) a VL comprising a FR1 comprising a sequence set forth in SEQ ID NO: 27, a FR2 comprising a sequence set forth between in SEQ ID NO: 28, a FR3 comprising a sequence set forth in SEQ ID NO: 29, and a FR4 comprising a sequence set forth in SEQ ID NO: 18; or
(v) a VH comprising a FR1 comprising a sequence set forth in SEQ ID NO: 24, a FR2 comprising a sequence set forth between in SEQ ID NO: 25, a FR3 comprising a sequence set forth in SEQ ID NO: 26, and a FR4 comprising a sequence set forth in SEQ ID NO: 14; and a VL comprising a FR1 comprising a sequence set forth in SEQ ID NO: 27, a FR2 comprising a sequence set forth between in SEQ ID NO: 28, a FR3 comprising a sequence set forth in SEQ ID NO: 29, and a FR4 comprising a sequence set forth in SEQ ID NO: 18.

### Claim 12 (depends on 10)

The antigen binding domain of claim 10, further comprising at least one of:
(i) a VH comprising a framework region (FR) 1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 68, a FR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set in SEQ ID NO: 69, a FR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 70, and a FR4 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 63;
(ii) a VL comprising a FR1 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 71, a FR2 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 72, a FR3 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 73, and a FR4 comprising a sequence at least about 80%, at least 85%, at least 90%, at least 91% at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a sequence set forth in SEQ ID NO: 67;
(iii) a VH comprising a FR1 comprising a sequence set forth in SEQ ID NO: 68, a FR2 comprising a sequence set forth between in SEQ ID NO: 69, a FR3 comprising a sequence set forth in SEQ ID NO: 70, and a FR4 comprising a sequence set forth in SEQ ID NO: 63;
(iv) a VL comprising a FR1 comprising a sequence set forth in SEQ ID NO: 71, a FR2 comprising a sequence set forth between in SEQ ID NO: 72, a FR3 comprising a sequence set forth in SEQ ID NO: 73, and a FR4 comprising a sequence set forth in SEQ ID NO: 67; or
(v) a VH comprising a FR1 comprising a sequence set forth in SEQ ID NO: 68, a FR2 comprising a sequence set forth between in SEQ ID NO: 69, a FR3 comprising a sequence set forth in SEQ ID NO: 70, and a FR4 comprising a sequence set forth in SEQ ID NO: 63; and a VL comprising a FR1 comprising a sequence set forth in SEQ ID NO: 71, a FR2 comprising a sequence set forth between in SEQ ID NO: 72, a FR3 comprising a sequence set forth in SEQ ID NO: 73, and a FR4 comprising a sequence set forth in SEQ ID NO: 67

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The antigen binding protein of any one of claims 1 to 12, wherein the antigen binding protein is in the form of:
(i) a single chain Fv fragment (scFv);
(ii) a dimeric scFv (di-scFv); or
(iii) one of (i) or (ii) linked to a constant region of an antibody, Fc or a heavy chain constant domain (CH) 2 and/or CH3.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The antigen binding protein of any one of claims 1 to 12, wherein the antigen binding protein is in the form of:
(i) a diabody;
(ii) a triabody;
(iii) a tetrabody;
(iv) a Fab;
(v) a F(ab′)2;
(vi) a Fv;
(vii) a bispecific antibody or other form of multispecific antibody; or
(viii) one of (i) to (vii) linked to a constant region of an antibody, Fc or a heavy chain constant domain (CH) 2 and/or CH3.

### Claim 15

An anti-CCR8 antibody or antigen binding fragment thereof comprising a light chain variable region and a heavy chain variable region,
wherein said heavy chain variable region comprises:
a CDR H1 as set forth in SEQ ID NO: 5, a CDR H2 as set forth in SEQ ID NO: 6, and a CDR H3 as set forth in SEQ ID NO: 7; and
wherein said light chain variable region comprises:
a CDR L1 as set forth in SEQ ID NO: 8, a CDR L2 as set forth in SEQ ID NO: 9 and a CDR L3 as set forth in SEQ ID NO: 10.

### Claim 16 (depends on 15)

The anti-CCR8 antibody or antigen binding fragment thereof of claim 15, wherein the anti-CCR8 antibody or antigen binding fragment thereof comprises a light chain variable region that comprises:
a FR L1 as set forth in SEQ ID NO: 15, an FR L2 as set forth in SEQ ID NO: 16, a FR L3 as set forth in SEQ ID NO: 17 and a FR L4 as set forth in SEQ ID NO: 18; or
a FR L1 as set forth in SEQ ID NO: 64, an FR L2 as set forth in SEQ ID NO: 65, a FR L3 as set forth in SEQ ID NO: 66 and a FR L4 as set forth in SEQ ID NO: 67.

### Claim 17 (depends on 15, 16)

The anti-CCR8 antibody or antigen binding fragment thereof of claim 15 or 16, wherein the anti-CCR8 antibody or antigen binding fragment thereof comprises a heavy chain variable region that comprises:
a FR H1 as set forth in SEQ ID NO: 11, FR H2 as set forth in SEQ ID NO: 12, a FR H3 as set forth in SEQ ID NO: 13 and a FR H4 as set forth in SEQ ID NO: 14; or
a FR H1 as set forth in SEQ ID NO: 60, FR H2 as set forth in SEQ ID NO: 61, a FR H3 as set forth in SEQ ID NO: 62 and a FR H4 as set forth in SEQ ID NO: 63.

### Claim 18

An anti-CCR8 antibody or antigen binding fragment thereof, comprising a light chain variable region and a heavy chain variable region,
wherein said heavy chain variable region comprises:
a CDR H1 as set forth in SEQ ID NO: 19, a CDR H2 as set forth in SEQ ID NO: 20, and a CDR H3 as set forth in SEQ ID NO: 21; and
wherein said light chain variable region comprises:
a CDR L1 as set forth in SEQ ID NO: 22, a CDR L2 as set forth in SEQ ID NO: 23 and a CDR L3 as set forth in SEQ ID NO: 10.

### Claim 19 (depends on 18)

The anti-CCR8 antibody or antigen binding fragment thereof of claim 18, wherein the anti-CCR8 antibody or antigen binding fragment thereof comprises a light chain variable region that comprises:
a FR L1 as set forth in SEQ ID NO: 27, an FR L2 as set forth in SEQ ID NO: 28, a FR L3 as set forth in SEQ ID NO: 29 and a FR L4 as set forth in SEQ ID NO: 18; or
a FR L1 as set forth in SEQ ID NO: 71, an FR L2 as set forth in SEQ ID NO: 72, a FR L3 as set forth in SEQ ID NO: 73 and a FR L4 as set forth in SEQ ID NO: 67.

### Claim 20 (depends on 18, 19)

The anti-CCR8 antibody or antigen binding fragment thereof of claim 18 or 19, wherein the anti-CCR8 antibody or antigen binding fragment thereof comprises a heavy chain variable region that comprises:
a FR H1 as set forth in SEQ ID NO: 24, FR H2 as set forth in SEQ ID NO: 25, a FR H3 as set forth in SEQ ID NO: 26 and a FR H4 as set forth in SEQ ID NO: 14, or
a FR H1 as set forth in SEQ ID NO: 68, FR H2 as set forth in SEQ ID NO: 69, a FR H3 as set forth in SEQ ID NO: 70 and a FR H4 as set forth in SEQ ID NO: 63.

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

The anti-CCR8 receptor antibody or antigen binding fragment thereof of any one of claims 15 to 20, wherein the anti-CCR8 receptor antibody or antigen binding fragment thereof comprises a light chain variable region that comprises the sequence of SEQ ID NO: 2.

### Claim 22 (depends on 15, 16, 17, 18, 19, 20, 21)

The anti-CCR8 receptor antibody or antigen binding fragment thereof of any one of claims 15 to 21, wherein the anti-CCR8 antibody or antigen binding fragment thereof comprises a heavy chain variable region that comprises the sequence of SEQ ID NO: 1.

### Claim 23 (depends on 15, 16, 17, 18, 19, 20)

The anti-CCR8 receptor antibody or antigen binding fragment thereof of any one of claims 15 to 20, wherein the anti-CCR8 receptor antibody or antigen binding fragment thereof comprises a light chain variable region that comprises the sequence of SEQ ID NO: 84.

### Claim 24 (depends on 15, 16, 17, 18, 19, 20, 23)

The anti-CCR8 receptor antibody or antigen binding fragment thereof of any one of claims 15 to 20 and 23, wherein the anti-CCR8 antibody or antigen binding fragment thereof comprises a heavy chain variable region that comprises the sequence of SEQ ID NO: 83.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The antigen binding protein, anti-CCR8 antibody or antigen binding fragment thereof of any one of claims 1 to 24, wherein the antigen binding protein or anti-CCR8 receptor antibody or antigen binding fragment thereof further comprises at most 15, preferably, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and preferably having 0, 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or a combination thereof with respect to the amino acid sequence of the indicated SEQ ID NO.

### Claim 26 (depends on 25)

The antigen binding protein, anti-CCR8 antibody or antigen binding fragment thereof of claim 25, wherein the amino acid insertions, deletions, substitutions or a combination thereof are not in the CDRs.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The antigen binding protein of any one of claims 1 to 26, comprising human constant regions.

### Claim 28 (depends on 27)

The antigen binding protein of claim 27, wherein the human constant regions comprise the amino acid sequence as shown in SEQ ID Nos: 58 and/or 59.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A nucleic acid encoding an antigen binding protein, antibody or antigen binding fragment thereof of any one of claims 1 to 28.

### Claim 30 (depends on 29)

A vector comprising a nucleic acid of claim 29.

### Claim 31 (depends on 29, 30)

A cell comprising a vector of claim 30 or nucleic acid of claim 29.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A pharmaceutical composition comprising an antigen binding protein of any one of claims 1 to 8 or 17 to 20, antibody or antigen binding fragment thereof of any one of claims 9 to 20, nucleic acid of claim 21, vector of claim 22 or cell of claim 23 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A kit or article of manufacture comprising an antigen binding protein of any one of claims 1 to 14 or 25 to 28, antibody or antigen binding fragment thereof of any one of claims 15 to 28, nucleic acid of claim 29, vector of claim 30, cell of claim 31, or pharmaceutical composition of claim 32.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A method for producing an antigen binding protein of any one of claims 1 to 14 or 25 to 28, antibody or antigen binding fragment of any one of claims 15 to 28 comprising expressing a nucleic acid of claim 29 a cell or non-human animal.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method for the prevention or treatment a condition or disease associated with expression of CCR8 in an individual comprising the step of providing an antigen binding protein of any one of claims 1 to 14 or 25 to 28, antibody or antigen binding fragment thereof of any one of claims 15 to 28, nucleic acid of claim 29, vector of claim 30, cell of claim 31, or pharmaceutical composition of claim 32 to an individual requiring treatment for said condition or disease.

### Claim 36 (depends on 35)

The method of claim 35, wherein the disease or condition associated with expression of CCR8.

### Claim 37 (depends on 35, 36)

The method of claim 35 or 36, wherein the disease or condition is cancer.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

Use of an antigen binding protein of any one of claims 1 to 14 or 25 to 28, antibody or antigen binding fragment thereof of any one of claims 15 to 28, nucleic acid of claim 29, vector of claim 30, cell of claim 31, or pharmaceutical composition of claim 32 in the manufacture of a medicament for the treatment or prevention of cancer in a subject.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

An antigen binding protein of any one of claims 1 to 14 or 25 to 28, antibody or antigen binding fragment thereof of any one of claims 15 to 28, nucleic acid of claim 29, vector of claim 30, cell of claim 31, or pharmaceutical composition of claim 32 for use in the treatment or prevention of cancer in a subject.
